The goal in demanding the introduction of the mechanism was that multiple companies would immediately trigger independent reviews with US Government support, draw attention to problems in decision-making, essentially overwhelm the system, and force further reform discussions. None of this happened, the US Government quickly lost confidence in the industry, and the Australian Government more successfully leveraged the agreement outcome.
Why the failure of a hard-won process reveals so much about an intractable problem
January 16, 2024 Latest NewsBioPharmaNews of the Day
Latest Video
New Stories
-
This exchange on the HTA Review was about as underwhelming as it sounds
October 9, 2025 - - Latest News -
AusBiotech unveils international conference program for Australia’s biggest week in biotech
October 9, 2025 - - Australian Biotech -
Life sciences industry calls for stronger national strategy to support trials and innovation
October 9, 2025 - - Latest News -
Officials outline ongoing measures to address ADHD medicine shortages
October 9, 2025 - - Latest News -
Pharmaceutical spending to rise by around $10 billion, but still lose ground to other programs
October 9, 2025 - - Latest News -
Australian company reports positive outcome from collaboration
October 8, 2025 - - Australian Biotech -
CUREator opens $33 million funding round with CSL and AbbVie partnership
October 8, 2025 - - Latest News